Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015, Lasa Supergenerics has informed that Meeting of the Board of Director of the Company is scheduled to be held on Monday, April 11, 2022: to consider, approve and take on records Audited financial results of the Company for the quarter and year ended March 31, 2022, to consider and recommend the dividend for the financial year ended March 31, 2022, subject to the approval of the shareholders at the ensuing General Meeting of the Company and to discuss any other matter with the permission of the Chairperson. In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company’s Code of Conduct, the Trading Window shall continue to remain closed from March 21, 2022 till 48 hours after the declaration of the Audited financial results of the Company for the quarter and year ended March 31, 2022. This Intimation is also available on the company’s website at www.lasalabs.com and on the website of the stock Exchange at www.bseindia.com and www.nseindia.com.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.70 |
Dr. Reddys Lab | 1258.55 |
Cipla | 1559.20 |
Lupin | 2198.25 |
Zydus Lifesciences | 1004.00 |
View more.. |